Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for atopic dermatitis (AD) and psoriasis treatment.
A phase 2b, double-blind, vehicle-controlled study randomly assigned adolescents and adults with AD to receive tapinarof cream 0.5%, 1%, or vehicle, once or twice daily, for 12 weeks with a 4-week follow-up. Outcomes included Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), body surface area affected, pruritus numeric rating scale scores, patients' impressions of AD and pruritus symptom severity, and Patient-Oriented Eczema Measure (POEM) scores.
Overall, 191 of 247 randomized patients completed the study. Week 12 IGA responses were higher in the tapinarof groups versus the vehicle group, reaching statistical significance with tapinarof 1% twice daily, ≥75%/90% improvement in EASI from baseline were significantly higher in the tapinarof groups (except 0.5% once daily and 0.5% twice daily), EASI scores were significantly improved in all tapinarof groups, and body surface area affected was significantly reduced in the tapinarof groups (except 0.5% twice daily). More patients reported AD and pruritus symptom severity as very/moderately improved in tapinarof groups, and POEM improvements were observed in all groups. Most adverse events were mild or moderate.
Larger prospective studies are required to confirm the reported analyses.
Tapinarof is a potential important advance in topical medicine development for AD.Le texte complet de cet article est disponible en PDF.
Key words : atopic dermatitis, patient-reported outcomes, tapinarof, therapeutic aryl hydrocarbon receptor (AhR) modulating agent (TAMA), topical therapy
Abbreviations used : AD, AE, BSA, IGA, EASI, EASI75, EASI90, ITT, NRS, POEM, PRO
| Funding sources: Supported by Dermavant Sciences, Inc.
| Disclosure: Dr Paller is an investigator (without personal compensation) for AbbVie, AnaptysBio, Eli Lilly, Galderma, Incyte, LEO Pharma, Janssen, Novartis, and Sanofi-Regeneron and a consultant (with honoraria) for AbbVie, Amgen, Asana, Dermavant Sciences, Inc, Dermira, Galderma, Eli Lilly, Forte, LEO Pharma, Matrisys, Menlo, MorphoSys/Galapagos, Novartis, Pfizer, and Sanofi-Regeneron. Dr Stein Gold is an investigator, consultant, and speaker with honoraria for Galderma, LEO Pharma, Ortho Dermatologics, and Pfizer Inc; an investigator with research grants for Incyte, AbbVie, and Eli Lily; a consultant and speaker with honoraria for Mayne and Taro; and a consultant with honoraria and an investigator for Dermavant Sciences, Inc. Dr Soung has received research grants and/or honoraria as an investigator for AbbVie, Actavis, Actelion, Allergan, Boehringer Ingelheim, Cassiopea, Dermira, Eli Lilly, Galderma, Janssen, Kadmon Corporation, Kyowa Kirin, LEO Pharma, Menlo, Ortho Dermatologics, Pfizer, and UCB; an investigator and consultant for Novartis and Dermavant Sciences, Inc; a speaker for AbbVie, Actelion, Amgen Inc, Celgene Corporation, Dermira, Eli Lilly, the National Psoriasis Foundation (nonprofit), Novartis, Ortho Dermatologics, and Regeneron; and an advisor for Eli Lilly and LEO Pharma. Dr Tallman is an employee of Dermavant Sciences, Inc, with stock options. Dr Rubenstein is an employee of Dermavant Sciences, Inc, with stock options. Dr Gooderham has been an investigator, speaker, advisory board member, or consultant for AbbVie, Amgen, Akros, Arcutis, Bausch Health, Boehringer Ingelheim, Celgene, Dermavant Sciences, Inc, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and UCB.
| IRB approval status: Approval was obtained from the local ethics committee or IRB at each study center.
| Reprints not available from the authors.